Victory Capital Management Inc. bought a new position in shares of Abcam plc (NASDAQ:ABCM – Get Rating) during the 4th quarter, according to its most recent disclosure with the SEC. The fund bought 1,269,247 shares of the company’s stock, valued at approximately $19,749,000. Victory Capital Management Inc. owned 0.55% of Abcam at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. 1832 Asset Management L.P. bought a new position in shares of Abcam in the 1st quarter worth about $32,000. JPMorgan Chase & Co. raised its position in shares of Abcam by 48.7% in the 1st quarter. JPMorgan Chase & Co. now owns 3,044 shares of the company’s stock worth $56,000 after acquiring an additional 997 shares in the last quarter. Van ECK Associates Corp raised its position in shares of Abcam by 41.4% in the 4th quarter. Van ECK Associates Corp now owns 3,536 shares of the company’s stock worth $55,000 after acquiring an additional 1,035 shares in the last quarter. UBS Group AG raised its position in shares of Abcam by 520.3% in the 4th quarter. UBS Group AG now owns 4,249 shares of the company’s stock worth $66,000 after acquiring an additional 3,564 shares in the last quarter. Finally, New York State Common Retirement Fund bought a new position in shares of Abcam in the 4th quarter worth about $121,000. 13.91% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Separately, Royal Bank of Canada boosted their target price on Abcam from $21.50 to $23.00 in a research report on Friday, April 28th.
Abcam Stock Down 0.7 %
Abcam Company Profile
Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. Its principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex and multiplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, miRNA kits, biochemicals, and cell signaling pathway tools.
- Get a free copy of the StockNews.com research report on Abcam (ABCM)
- MarketBeat Week in Review – 5/15 – 5/19
- Applied Materials: Cracks In The Chip Recovery Or Time To Buy?
- Deere & Company Rallies On Farm Equipment Boom, Bullish Outlook
- How Many Roth IRAs Can You Have?
- Why You Should Consider Buying Nvidia Ahead Of Earnings
Receive News & Ratings for Abcam Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam and related companies with MarketBeat.com's FREE daily email newsletter.